

AngioDynamics Announces Ruling in VNUS Litigation

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Oct. 3, 2007--AngioDynamics, Inc. (NASDAQ:ANGO) today announced the denial of cross-motions for summary judgment issued in the U.S. District Court in the Northern District of California in the patent litigation brought by VNUS Medical Technologies against Diomed, AngioDynamics and Vascular Solutions.

In her ruling, Judge Chesney denied VNUS's motion for summary judgment of infringement, leaving that issue for trial. The court also denied defendants' motion that one patent was invalid in light of the prior art, and invalidity of all asserted patents for non-compliance with the written description and enablement requirements of the Patent Law, also leaving these issues for trial. The Judge deferred ruling on the defendants' motion that two of VNUS's patents are invalid due to prior art, asking VNUS to respond to issues raised by the defendants by October 19.

As a result of the Judge's rulings, the case will now proceed to a jury trial, which is currently scheduled to commence on October 29, 2007.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

Safe Harbor

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.

D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Investor Relations:
Jennifer Beugelmans, 646-201-5447

jbeugelmans@evcgroup.com
Doug Sherk, 646-201-5447
dsherk@evcgroup.com
Media:
Steve DiMattia, 646-201-5445
sdimattia@evcgroup.com

SOURCE: AngioDynamics, Inc.